Menu

Newly Discovered Hormone Explains Disease

Patients with neonatal progeroid syndrome lack a glucose-releasing hormone, while people with insulin resistance have an abundance.

Apr 15, 2016
Kerry Grens

WIKIMEDIA, HENRY GRAY (1918) ANATOMY OF THE HUMAN BODYNeonatal progeroid syndrome (NPS) is a rare genetic disease that typically claims patients’ lives in infancy. In exceptional cases, patients can live into adulthood. College student Abigail Solomon of Austin, Texas, is one such patient; her participation in a study published yesterday (April 14) in Cell has led to the discovery of a peptide hormone involved in glucose release.

Researchers seeking to find a cause for Solomon’s condition showed that not only is this hormone, called asprosin, lacking among people with NPS, it is overabundant among people with insulin resistance. Administering an antibody against asprosin to diabetic mice dropped their plasma insulin levels—suggesting the hormone might be a target to treat diabetes.

“This result brought us full circle. We started with an extremely rare genetic disorder, and using information learned from those patients, discovered a new hormone that can be targeted to treat a different disease that affects many more people,” study leader Atul Chopra of Baylor College of Medicine said in a press release.

Asprosin, Chopra’s team found, is produced by fat, which is lacking among those with NPS. The hormone heads to the liver where it prompts glucose release.

Solomon was one of two people with NPS who were analyzed for the study. “Dr. Chopra’s work not only paves the way to find a treatment for people with my disorder—NPS, something I have lived with my entire life—but also a treatment for diabetes,” she said in the statement. “I feel proud and honored to have been given an opportunity to participate in this process.”

 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.